Rapportering af bivirkninger og uønskede haendelser i randomiserede kliniske forsøg
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Rapportering af bivirkninger og uønskede haendelser i randomiserede kliniske forsøg. / Hemmingsen, Bianca Betina; Støy, Lina; Wetterslev, Jørn; Tarnow, Lise; Bach, Karin Ursula Friis; Christensen, Louise Lundby; Salas, Nader; Gluud, Christian Nyfeldt; Copenhagen Insulin Metformin Therapy Trial-Gruppen ; Perrild, Hans Jørgen Duckert; Krarup, Thure; Christensen, Louise Lundby; Vestergaard, Henrik.
In: Ugeskrift for Laeger, Vol. 172, No. 35, 30.08.2010, p. 2381-4.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Rapportering af bivirkninger og uønskede haendelser i randomiserede kliniske forsøg
AU - Hemmingsen, Bianca Betina
AU - Støy, Lina
AU - Wetterslev, Jørn
AU - Tarnow, Lise
AU - Bach, Karin Ursula Friis
AU - Christensen, Louise Lundby
AU - Salas, Nader
AU - Gluud, Christian Nyfeldt
AU - Copenhagen Insulin Metformin Therapy Trial-Gruppen
AU - Perrild, Hans Jørgen Duckert
AU - Krarup, Thure
AU - Christensen, Louise Lundby
AU - Vestergaard, Henrik
PY - 2010/8/30
Y1 - 2010/8/30
N2 - "Good clinical practice" (GCP) is an international guideline on how to conduct clinical trials on medical products involving human participants. Danish statute follows the EU trial directive (2001/20/EF) including the GCP guidelines. This article summarises the practical implementation of reporting adverse events and adverse reactions to the Danish Medicines Agency and the regional ethics committee based on the protocol of the ongoing Copenhagen Insulin and Metformin Therapy (CIMT) trial.
AB - "Good clinical practice" (GCP) is an international guideline on how to conduct clinical trials on medical products involving human participants. Danish statute follows the EU trial directive (2001/20/EF) including the GCP guidelines. This article summarises the practical implementation of reporting adverse events and adverse reactions to the Danish Medicines Agency and the regional ethics committee based on the protocol of the ongoing Copenhagen Insulin and Metformin Therapy (CIMT) trial.
KW - Adverse Drug Reaction Reporting Systems
KW - Denmark
KW - European Union
KW - Guideline Adherence
KW - Guidelines as Topic
KW - Humans
KW - Hypoglycemic Agents
KW - Insulin
KW - Metformin
KW - Randomized Controlled Trials as Topic
M3 - Tidsskriftartikel
C2 - 20825743
VL - 172
SP - 2381
EP - 2384
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 35
ER -
ID: 34162749